Nutex Health (NASDAQ:NUTX) Stock Price Up 12.7% - Here's What Happened

Key Points

• Nutex Health shares rose 12.7% in Friday midday trading to $171.30, though trading volume was 51% below the average session level.
• Analyst sentiment remains favorable, with three Buy ratings and two Hold ratings producing a consensus “Moderate Buy” rating and an average price target of $243.33.
• Several institutional investors recently initiated or increased positions in Nutex Health, but institutional ownership remains relatively low at 5.32%.

Nutex Health Inc. (NASDAQ:NUTX - Get Free Report) was up 12.7% during mid-day trading on Friday . The company traded as high as $171.42 and last traded at $171.30. 83,451 shares traded hands during trading, a decline of 51% from the average session volume of 170,086 shares. The stock had previously closed at $151.93.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Lake Street Capital started coverage on shares of Nutex Health in a research note on Tuesday, June 2nd. They issued a "buy" rating and a $235.00 price target on the stock. Wall Street Zen downgraded shares of Nutex Health from a "strong-buy" rating to a "buy" rating in a research report on Monday, July 20th. B. Riley Financial began coverage on shares of Nutex Health in a research report on Friday, June 26th. They set a "buy" rating and a $290.00 price objective for the company. Weiss Ratings upgraded Nutex Health from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, July 28th. Finally, Zacks Research upgraded Nutex Health to a "hold" rating in a research note on Monday, June 29th. Three analysts have rated the stock with a Buy rating and two have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $243.33.

Nutex Health Stock Up 11.5%

The stock has a fifty day moving average price of $156.57 and a two-hundred day moving average price of $128.97. The company has a market cap of $1.17 billion, a price-to-earnings ratio of 13.02 and a beta of 0.24. The company has a quick ratio of 3.12, a current ratio of 3.14 and a debt-to-equity ratio of 0.66.

Institutional Trading of Nutex Health

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Global Retirement Partners LLC bought a new stake in Nutex Health in the 2nd quarter valued at about $342,000. Bank of New York Mellon Corp bought a new position in shares of Nutex Health during the second quarter worth approximately $3,956,000. GSA Capital Partners LLP acquired a new stake in shares of Nutex Health in the second quarter valued at approximately $307,000. Plan Group Financial LLC acquired a new stake in shares of Nutex Health in the second quarter valued at approximately $282,000. Finally, Bank of America Corp DE raised its position in shares of Nutex Health by 52.3% in the first quarter. Bank of America Corp DE now owns 9,027 shares of the company's stock valued at $858,000 after buying an additional 3,101 shares in the last quarter. Institutional investors and hedge funds own 5.32% of the company's stock.

Nutex Health Company Profile

Nutex Health, Inc NASDAQ: NUTX is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source